<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Antibody Design | BM Sci-Tech Memento</title>
    <link>https://example.com/tag/antibody-design/</link>
      <atom:link href="https://example.com/tag/antibody-design/index.xml" rel="self" type="application/rss+xml" />
    <description>Antibody Design</description>
    <generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><lastBuildDate>Thu, 22 Sep 2022 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://example.com/media/icon_hu1efa9af2edf414d45fb59503b457ea16_13437_512x512_fill_lanczos_center_3.png</url>
      <title>Antibody Design</title>
      <link>https://example.com/tag/antibody-design/</link>
    </image>
    
    <item>
      <title>Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth</title>
      <link>https://example.com/article/36138032/</link>
      <pubDate>Thu, 22 Sep 2022 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/36138032/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;One major limitation of neutralizing antibody-based COVID-19 therapy is the requirement of costly cocktails to reduce emergence of antibody resistance. Here we engineer two bispecific antibodies (bsAbs) using distinct designs and compared them with parental antibodies and their cocktail. Single molecules of both bsAbs block the two epitopes targeted by parental antibodies on the receptor-binding domain (RBD). However, bsAb with the IgG-(scFv)2 design (14-H-06) but not the CrossMAb design (14-crs-06) shows increased antigen-binding and virus-neutralizing activities against multiple SARS-CoV-2 variants as well as increased breadth of neutralizing activity compared to the cocktail. X-ray crystallography and cryo-EM reveal distinct binding models for individual cocktail antibodies, and computational simulations suggest higher inter-spike crosslinking potentials by 14-H-06 than 14-crs-06. In mouse models of infections by SARS-CoV-2 and multiple variants, 14-H-06 exhibits higher or equivalent therapeutic efficacy than the cocktail. Rationally engineered bsAbs represent a cost-effective alternative to antibody cocktails and a promising strategy to improve potency and breadth.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody</title>
      <link>https://example.com/article/35344711/</link>
      <pubDate>Thu, 14 Apr 2022 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/35344711/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Highlights&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Conserved epitopes outside of the RBM of SARS-CoV-2 spike RBD&lt;/li&gt;
&lt;li&gt;A bispecific single-domain antibody (bn03) broadly neutralizes SARS-CoV-2 variants&lt;/li&gt;
&lt;li&gt;Two arms of bn03 can bind simultaneously and synergistically to one RBD of spike trimer&lt;/li&gt;
&lt;li&gt;Inhalation of bn03 can effectively treat SARS-CoV-2 infection in hACE2 mice&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;strong&gt;Summary&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;The effectiveness of SARS-CoV-2 vaccines and therapeutic antibodies have been limited by the continuous emergence of viral variants and by the restricted diffusion of antibodies from circulation into the sites of respiratory virus infection. Here, we report the identification of two highly conserved regions on the Omicron variant receptor-binding domain recognized by broadly neutralizing antibodies. Furthermore, we generated a bispecific single-domain antibody that was able to simultaneously and synergistically bind these two regions on a single Omicron variant receptor-binding domain as revealed by cryo-EM structures. We demonstrated that this bispecific antibody can be effectively delivered to lung via inhalation administration and exhibits exquisite neutralization breadth and therapeutic efficacy in mouse models of SARS-CoV-2 infections. Importantly, this study also deciphered an uncommon and highly conserved cryptic epitope within the spike trimeric interface that may have implications for the design of broadly protective SARS-CoV-2 vaccines and therapeutics.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
  </channel>
</rss>
